Novartis AG (NVS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

NVS Novartis AG

Watchlist

105.670
-0.780-0.73%

Close Nov 11 16:00 ET

105.750
+0.080+0.08%

Post 20:02 ET

211.26BMarket Cap12.40P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Announces Target Price $125
Moomoo News13:31 ET · Ratings
J.P. Morgan Remains a Hold on Novartis AG (NOVN)
TipRanksNov 7 08:51 ET · Ratings
Novartis AG Falls Wednesday
Dow JonesNov 6 12:15 ET
Tango Stock Plunges 28% Amid Pipeline Updates, Q3 Earnings Report
Seeking AlphaNov 6 10:29 ET
European Equities Traded in the US as American Depositary Receipts Edge Higher Tuesday
MT NewswiresNov 5 11:40 ET
Seaport Therapeutics Names Lauren White as Chief Financial Officer
BusinesswireNov 5 07:00 ET

Comments

10xStockPicks

Nov 8 08:28

This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months

Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary...

+18

Asherboy88

Nov 5 09:58

$Novartis AG (NVS.US)$ Why it keeps dropping ? didn't see any bad news

Stock_Drift

Oct 18 05:56

$Novartis AG (NVS.US)$

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

Growth Investor27

Oct 15 09:01

Buyout offer Could be $10+ For Esperion And Could Happen Before 2025

$Esperion Therapeutics (ESPR.US)$ The recent analyst note from Jeff sugest Esperion might sell the entire rights for Bempedoic Acid. Fair valuation on the rights would be above $1.5 billion, based on future milestones $900 million, future royalties & patents, the current formulation patent has exp date Dec 2031. The potential yearly sales in the U.S could reach $4 billion by 2027.
Esperion could also partner in the U.S .
Keep an...